Artesunate/amodiaquine

From WikiProjectMed
Jump to navigation Jump to search
Artesunate/amodiaquine
Combination of
ArtesunateAntimalarial
AmodiaquineAntimalarial
Names
Trade namesCamoquin, others[1]
Other namesASAQ
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
use
By mouth[2]
Defined daily dosenot established[3]
 ☒N☑Y (what is this?)  (verify)

Artesunate/amodiaquine, sold under the trade name Camoquin among others, is a medication used for the treatment of malaria.[4][5] It is a fixed-dose combination of artesunate and amodiaquine.[4] Specifically it recommended for acute uncomplicated Plasmodium falciparum malaria.[6] It is taken by mouth.[7]

Common side effects include loss of appetite, nausea, abdominal pain, sleepiness, trouble sleeping, and cough.[8] Safety in pregnancy is not clear; however, the medication may be used if others are not possible.[8] It is believed to be safe for use during breastfeeding.[8] Artesunate and amodiaquine are both antimalarial medication; however, work by different mechanisms.[8]

Artesunate/amodiaquine was commercially launched in 2007.[9] It is on the World Health Organization's List of Essential Medicines.[4] Artesunate/amodiaquine is available as a generic medication.[9] The wholesale cost in the developing world is about US$0.85 to US$1.52 for a course of treatment.[7] As of 2014 it is not commercially available in the United States or United Kingdom.[1][10]

Medical uses

Early clinical trials showed that a once-a-day dosage was effective.[11] It was subsequently shown to be equally effective as artemether/lumefantrine,[12] although it is likely to be more effective in the field due to its simpler once-a-day dosage compared to artemether/lumefantrine twice-per-day dosage.

Dosage

The defined daily dose is not established.[2] For those who weight more than 35 kg the dose is 200/540 mg one a day, for those who weight 18 to 35 kg the dose is 100/270 mg once a day, for those who weight 9 to 18 kg the dose is 50/135 mg once per day, and for those who weight 4.5 to 9 kg the dose is 25/67.5 mg once per day.[13] Treatment is for three days.[13]

Society and culture

Artesunate/amodiaquine was commercially launched in 2007 as an affordable treatment for malaria, devised by DNDi in partnership with Sanofi-Aventis.[9] ASAQ was handed over to the MMV Access and Product Management Team in May 2015.[14]

References

  1. 1.0 1.1 Ainsworth, Sean B. (2014). Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. John Wiley & Sons. p. 75. ISBN 9781118819517. Archived from the original on 2016-12-20.
  2. 2.0 2.1 "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 20 September 2020.
  3. Cite error: Invalid <ref> tag; no text was provided for refs named MSH2015
  4. 4.0 4.1 4.2 World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  5. Oyakhirome S, Pötschke M, Schwarz NG, et al. (March 2007). "Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children". Malar. J. 6: 29. doi:10.1186/1475-2875-6-29. PMC 1831475. PMID 17352806.
  6. World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 187. hdl:10665/44053. ISBN 9789241547659.
  7. 7.0 7.1 "Artesunate + Amodiaquine". International Drug Price Indicator Guide. Retrieved 8 December 2016.
  8. 8.0 8.1 8.2 8.3 "Artesunate Amodiaquine Winthrop" (PDF). WIPO. August 2010. Archived (PDF) from the original on 24 October 2016. Retrieved 12 December 2016.
  9. 9.0 9.1 9.2 "New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available – DNDi". www.dndi.org. 1 March 2007. Archived from the original on 20 December 2016. Retrieved 12 December 2016.
  10. Goldman, Lee; Schafer, Andrew I. (2015). Goldman-Cecil Medicine. Elsevier Health Sciences. p. 2112. ISBN 9780323322850. Archived from the original on 2016-12-20.
  11. Ndiaye, Jean; Randrianarivelojosia, Milijaona; Sagara, Issaka; Brasseur, Philippe; Ndiaye, Ibrahima; Faye, Babacar; Randrianasolo, Laurence; Ratsimbasoa, Arsène; Forlemu, Doris; Moor, Vicky; Traore, Aminata; Dicko, Yahia; Dara, Niawanlou; Lameyre, Valérie; Diallo, Mouctar; Djimde, Abdoulaye; Same-Ekobo, Albert; Gaye, Oumar (June 2009). "Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria". Malaria Journal. 8: 125. doi:10.1186/1475-2875-8-125. PMC 2698916. PMID 19505304. Archived from the original on 19 September 2011. Retrieved 18 January 2013.
  12. Nidiaye, Jean-Louis A; Faye, Babacar; Gueye, Ali; Tine, Roger; Ndiaye, Daouda; Tchania, Corinne; Ndiaye, Ibrahima; Barry, Aichatou; Cissé, Badara; Lameyre, Valérie; Gaye, Oumar (2011). "Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial". Malaria Journal. 10: 237. doi:10.1186/1475-2875-10-237. PMC 3171378. PMID 21838909. Archived from the original on 10 October 2014. Retrieved 18 January 2013.
  13. 13.0 13.1 "ARTESUNATE/AMODIAQUINE = AS/AQ oral - Essential drugs". medicalguidelines.msf.org. Retrieved 25 August 2020.
  14. "DNDi passes the ball to MMV | Medicines for Malaria Venture". www.mmv.org. Retrieved 2020-02-13.

External links

Identifiers: